What Prelude Therapeutics Incorporated's executives and directors are doing with their own shares, from SEC Form 3/4/5 filings — separating what the filings state (awards, withholding, disclosed plans) from what only the pattern of dates shows.
| 3 months | 12 months | |
|---|---|---|
| Open-market buys | 0 | 4 |
| Sells | 0 | 0 |
| Total trades | 0 | 5 |
| 3 months | 12 months | |
|---|---|---|
| Acquired | 0 | 5,630,630 |
| Disposed | 0 | 1,407,000 |
| Net activity | +0 | +4,223,630 |
View rich charts and dive into the patterns of specific insiders — who is accumulating, who is winding down, and which sale explanations the filings actually support.
| Insider | Relation | Date | Transaction | Shares | Price | Value | Shares held |
|---|---|---|---|---|---|---|---|
| Ra Capital MANAGEMENT, L.p. | 10% owner | Apr 27 | Other Transaction · J | −1,407,000 | — | — | 6,475,882 |
| Orbimed Advisors Llc | Director | Apr 21 | Open-market buy · P | +1,126,126 | $4.44 | +$5M | 1,126,126 |
| Orbimed Advisors Llc | Director | Apr 21 | Open-market buy · P | +1,689,189 | $4.44 | +$7.5M | 11,808,945 |
| Bonita David P | Director | Apr 21 | Open-market buy · P | +1,126,126 | $4.44 | +$5M | 1,126,126 |
| Bonita David P | Director | Apr 21 | Open-market buy · P | +1,689,189 | $4.44 | +$7.5M | 11,808,945 |
| Huang Jane | President, CMO | Oct 04 | Withheld — tax / exercise cost · F | −3,355 | $1.47 | −$4.93K | 86,917 |
| Huang Jane | President, CMO | Oct 04 | Exercise / conversion · M | +9,375 | — | — | 90,272 |
| Huang Jane | President, CMO | Jul 04 | Withheld — tax / exercise cost · F | −3,355 | $0.79 | −$2.66K | 80,897 |
| Huang Jane | President, CMO | Jul 04 | Exercise / conversion · M | +9,375 | — | — | 84,252 |
| Huang Jane | President, CMO | Apr 04 | Withheld — tax / exercise cost · F | −3,355 | $0.68 | −$2.26K | 74,877 |
| Huang Jane | President, CMO | Apr 04 | Exercise / conversion · M | +9,375 | — | — | 78,232 |
| Vaddi Krishna | CEO | Mar 25 | Open-market buy · P | +675,000 | $0.69 | +$467K | 1,999,296 |
| Combs Andrew | Chief Chemistry Officer | Mar 25 | Open-market buy · P | +100,000 | $0.69 | +$69.3K | 480,123 |
| Vaddi Krishna | CEO | Mar 21 | Open-market buy · P | +15,000 | $0.73 | +$11K | 1,324,296 |
| Vaddi Krishna | CEO | Mar 20 | Open-market buy · P | +5,416 | $0.73 | +$3.95K | 1,309,296 |
| Vaddi Krishna | CEO | Mar 17 | Open-market buy · P | +9,106 | $0.75 | +$6.83K | 1,303,880 |
| Vaddi Krishna | CEO | Mar 14 | Open-market buy · P | +29,999 | $0.75 | +$22.6K | 1,294,774 |
| Vaddi Krishna | CEO | Mar 13 | Open-market buy · P | +50,000 | $0.72 | +$35.8K | 1,264,775 |
| Vaddi Krishna | CEO | Mar 12 | Open-market buy · P | +47,500 | $0.71 | +$33.7K | 1,214,775 |
| Huang Jane | President, CMO | Jan 04 | Withheld — tax / exercise cost · F | −3,859 | $1.39 | −$5.36K | 68,857 |
Loading...